Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
Bin Qiu, Kaican Cai, Chun Chen, Jun Chen, Ke‐Neng Chen, Qixun Chen, Chao Cheng, Tianyang Dai, Junqiang Fan, Zhaohui Fan, Jian Hu, Weidong Hu, Yunchao Huang, Gening Jiang, Jie Jiang, Tao Jiang, Wenjie Jiao, Hecheng Li, Qiang Li, Yongde Liao, Hongxu Liu, Junfeng Liu, Lunxu Liu, Yang Liu, Hao Long, Qingquan Luo, Haitao Ma, Naiquan Mao, Xiaojie Pan, Fengwei Tan, Lijie Tan, Hui Tian, Dong Wang, Wenxiang Wang, Wei Li, Nan Wu, Qingchen Wu, Jiaqing Xiang, Shidong Xu, Lin Yang, Hao Zhang, Lanjun Zhang, Peng Zhang, Yi Zhang, Zhenfa Zhang, Kunshou Zhu, Yuming Zhu, Sang‐Won Um, In‐Jae Oh, Yusuke Tomita, Satoshi Watanabe, Takeo Nakada, Nobuhiko Seki, Toyoaki Hida, Shinji Sasada, Junji Uchino, Haruhiko Sugimura, Said Dermime, Federico Cappuzzo, Stefania Rizzo, William C. Cho, Pierfilippo Crucitti, Filippo Longo, Kye Young Lee, Dirk De Ruysscher, Ben Vanneste, Muhammad Furqan, Jessica C. Sieren, Sai Yendamuri, Kenneth W. Merrell, Julian R. Molina, Giulio Metro, Raffaele Califano, Stefano Bongiolatti, Mariano Provencio, Paul Hofman, Shugeng Gao, Jie He
Abstract
The treatment of lung cancer is one of the major challenges in the field of oncology. According to statistics from the National Cancer Center of China in 2015, lung cancer has the highest incidence and mortality, with 733,300 new cases and 610,200 deaths across the country (1). About 85% of lung cancers are non-small cell lung cancer (NSCLC), of which 30% to 40% are considered resectable tumors, including most stage I-II and a small portion of stage IIIA tumors (2).